NanoBioConvergence: The Value of Intellectual Property: Commercialization & Acquisition March 23, 2005

NanoBioConvergence presents:

The Value of Intellectual Property: Commercialization & Acquisition

Wed, Mar 23, 6:00pm-9:00pm, Palo Alto

MORE INFO: http://www.nanobioconvergence.org

IF YOU ATTEND JUST ONE INTELLECTUAL PROPERTY EVENT IN 2005, THEN THIS IS THE ONE!

Come join us for an evening of lively panel discussions and learn from the experts about the critical strategies for leveraging and maximizing the value of intellectual property where nanotechnology and biotechnology converge.

Scheduled panelists include:
* Terry Fetterhoff, Director, Chief Technology Office, Roche Diagnostics
* Mark Menna, Principal, Nanoverse
* John Wetherell, Partner, Life Sciences, Pillsbury Winthrop

WHY YOU NEED TO ATTEND…
Intellectual property plays a key role in the development and valuation of new technologies. Along the sometimes rocky path to commercialization, IP value changes in relation to market value. Our panel of experts discuss the challenges of commercializing new technologies and the key strategies of how to avoid the pitfalls. Learn what it takes to maximize the ROI of intellectual property as it goes from spin-out to acquisition.

TIME:
Networking begins @ 6:00PM
Program/discussions begin promptly @ 7:00PM

This is expected to be a very popular event. Space is limited so register early
We look forward to seeing you at this informative event.

DATE & TIME:
Wednesday, March 23
6:00pm-9:00pm

LOCATION:
The Offices of Pillsbury Winthrop
2475 Hanover Street
Palo Alto, CA, 94304
http://www.pillsburywinthrop.com/locations/office.asp?officeid=000058491444

COST & REGISTRATION:
$25 pre-reg, $35 at the door, $10 students.
http://www.acteva.com/go/nanobiocon

MORE INFO:
Website: http://www.nanobioconvergence.org
Email: ltmazzola@earthlink.net
Phone: 650-465-2718

About NanoBioConvergence:
NanoBioConvergence is a non-profit organization that showcases applications of nanotech in the Life Sciences. Monthly programs present new technologies and discuss development, investment and IP issues vital to this emerging field.